Summary

Global Automatic Coagulation System Market was valued at USD 2.74 Billion in 2024 and is expected to reach USD 4.06 Billion by 2030 with a CAGR of 6.72% during the forecast period. The Global Automatic Coagulation System Market is primarily driven by the increasing prevalence of coagulation disorders, such as hemophilia, deep vein thrombosis, and pulmonary embolism. These conditions require accurate and efficient monitoring of blood coagulation levels, fueling demand for automated coagulation testing systems. The growing aging population, which is more prone to clotting-related issues, is contributing to the market’s expansion. Technological advancements, such as the integration of real-time monitoring, artificial intelligence, and enhanced user interfaces, are also driving adoption by improving the accuracy, efficiency, and ease of use in diagnostic settings. The increasing awareness of the importance of precise coagulation management in both clinical and home care settings is encouraging healthcare providers to adopt automated coagulation systems for improved patient outcomes.
Key Market Drivers
Increasing Prevalence of Coagulation Disorders
The increasing prevalence of coagulation disorders is one of the most significant drivers of the global automatic coagulation system market. Conditions like hemophilia, deep vein thrombosis (DVT), pulmonary embolism, and other clotting-related diseases are becoming more common, particularly with the aging population. These conditions require regular and precise monitoring of coagulation levels to ensure proper management and treatment, preventing complications such as excessive bleeding or blood clots. Traditional manual testing methods, while still in use, are being phased out in favor of automated systems that offer more rapid and accurate results. Globally, over 200,000 people are living with some form of hemophilia, though new data suggests the condition may be underdiagnosed, with the true number potentially exceeding 1.1 million. In the United States, the exact prevalence is unclear, but estimates indicate that around 33,000 individuals assigned male at birth are affected by hemophilia. The condition predominantly impacts those assigned male at birth, with one study showing that individuals assigned female at birth make up about 18% of mild hemophilia cases and less than 1% of severe cases. Hemophilia is most common among white and Hispanic populations, while it is less prevalent among Black and Asian individuals.
Automated coagulation systems reduce human error, increase workflow efficiency, and provide faster diagnostic results, which is crucial for timely clinical decision-making. This technology is especially vital for patients undergoing surgeries or those on anticoagulant medications, such as warfarin, where precise management of blood clotting is necessary. As these disorders become more widespread, particularly in aging populations, the demand for reliable automated systems for coagulation testing is rising, thus driving market growth. Patients with chronic clotting conditions or those requiring long-term anticoagulation therapy benefit from continuous monitoring facilitated by these automated systems, further expanding their market potential.
Technological Advancements in Coagulation Testing Systems
Technological advancements have played a pivotal role in the evolution of coagulation testing systems. Automation has revolutionized the field, providing systems with the ability to perform highly sophisticated tasks such as real-time monitoring, enhanced data accuracy, and integration with digital platforms. Innovations like artificial intelligence (AI) and machine learning are being integrated into these systems, enabling automated coagulation systems to analyze and predict coagulation disorders with higher precision. In November 2022, HemoSonics, a medical device company, announced that it had received US FDA clearance for its Quantra Hemostasis System with the QStat cartridge. This system utilizes ultrasound technology to assess the coagulation properties of whole blood samples and is approved for use in point-of-care settings, including operating rooms, emergency departments, and ICUs.
For example, AI algorithms can analyze coagulation profiles and detect early signs of abnormalities, helping healthcare professionals take timely preventive measures. Automation also reduces the labor and time required for traditional manual testing processes, making coagulation testing faster and more efficient. Modern coagulation analyzers now offer more than just basic clotting time measurements; they can evaluate multiple coagulation factors, providing more comprehensive data that can be used for diagnostic and therapeutic purposes. This is particularly important for managing complex conditions like liver disease or when assessing the impact of anticoagulant therapy. As these technologies continue to advance, automatic coagulation systems will become even more accurate, efficient, and easy to use, further boosting their adoption in both clinical and point-of-care settings.
Growing Demand for Point-of-Care Testing
Point-of-care (POC) testing is an emerging trend in healthcare that is driving the growth of the automatic coagulation system market. POC devices allow for diagnostic testing outside traditional laboratory settings, providing results quickly and facilitating immediate treatment decisions. This has proven particularly beneficial for patients who require frequent coagulation monitoring, such as those undergoing long-term anticoagulation therapy. Traditional coagulation tests are often performed in centralized labs, which can delay results and treatment adjustments. In May 2022, CAMC's Automated Procedures Lab (APL) announced an upgrade to its facilities, expanding its automation line to include hematology and coagulation, along with the introduction of auto-verification using the new system.
With POC coagulation systems, healthcare providers can access real-time data on-site, leading to faster decision-making. These systems are becoming increasingly important in emergency care, ambulatory clinics, and even at-home monitoring. For instance, patients on warfarin or other blood thinners must maintain stable International Normalized Ratio (INR) levels to avoid bleeding or clotting risks. POC coagulation systems allow for continuous monitoring and immediate feedback, enabling healthcare providers to adjust treatment quickly. The convenience and cost-effectiveness of POC testing systems contribute to their growing adoption, making it an attractive solution in both developed and developing regions. As the healthcare industry moves toward decentralization, POC coagulation testing systems are expected to see significant growth.
Aging Population and Increased Risk of Coagulation Disorders
The global aging population is a critical factor driving the demand for automatic coagulation systems. As individuals age, they are more prone to various health conditions, including clotting disorders such as thrombophilia, hemophilia, and other coagulation-related diseases. Age-related factors, such as a decrease in the body’s ability to produce certain clotting factors or an increased likelihood of developing cardiovascular conditions, contribute to the rising incidence of these disorders in older adults. All countries are facing significant challenges in preparing their health and social systems to effectively address the impacts of demographic shifts. By 2050, 80% of the global population aged 60 and older will reside in low- and middle-income countries. The pace of population aging is accelerating at a much faster rate than in the past. In 2020, there were more individuals aged 60 and older than there were children under the age of 5. Between 2015 and 2050, the percentage of the global population over 60 will nearly double, rising from 12% to 22%.
Consequently, elderly patients require regular monitoring of their coagulation levels to prevent serious health complications like stroke, myocardial infarction, or excessive bleeding. Automated coagulation systems are especially beneficial for this demographic, as they provide consistent and accurate monitoring with minimal user intervention. These systems enable healthcare providers to track coagulation profiles regularly and make adjustments to treatment regimens, such as anticoagulant therapy, which is common among elderly patients. With the global population aging, the need for reliable, user-friendly, and efficient coagulation testing systems will continue to grow, ensuring that automatic coagulation systems remain an essential tool in managing the health of older individuals.
Key Market Challenges
High Initial Costs
One of the primary challenges faced by the global automatic coagulation system market is the high initial investment required for purchasing and installing these systems. Automated coagulation testing systems are sophisticated and technologically advanced, often resulting in significant upfront costs for hospitals, laboratories, and other healthcare facilities. Smaller and resource-constrained medical centers may struggle to afford these systems, limiting their adoption, especially in emerging markets. The maintenance and calibration of these systems further contribute to ongoing costs, which could deter healthcare providers from adopting them, despite the long-term benefits in terms of efficiency and accuracy. Although the operational efficiencies and cost savings can offset the initial expenditure, the high price remains a barrier for many healthcare institutions, especially those in developing regions.
Technical Complexity and Training Requirements
Another challenge is the technical complexity associated with using automated coagulation systems. These systems are often equipped with advanced features and capabilities, which require specialized training for laboratory technicians and healthcare providers. Without proper training, there is a risk of misinterpretation of results or inefficient use of the system. For healthcare institutions, investing in continuous staff education and ensuring proper training programs are available becomes a recurring expense. Healthcare professionals must stay updated with technological advancements and system upgrades, which can be time-consuming. As the market for these systems grows, the need for skilled personnel to operate and maintain them increases, creating challenges in recruitment and training for many institutions.
Integration with Existing Healthcare Infrastructure
Integration of automated coagulation systems with existing healthcare infrastructure, such as electronic health records (EHR), laboratory information systems (LIS), and patient monitoring platforms, can present significant challenges. While many advanced coagulation testing systems are designed to be compatible with these platforms, integration is not always seamless. Incompatibilities or technical issues during integration may cause delays in implementation and could potentially affect the accuracy and efficiency of test result sharing. Healthcare providers may face challenges in upgrading their infrastructure to support these advanced systems, particularly in older or smaller medical facilities. Without proper integration, the full potential of automated coagulation systems—such as real-time data access and continuous patient monitoring—cannot be fully realized, hindering the system's overall effectiveness.
Key Market Trends
Increase in Hospital and Laboratory Automation
The increasing trend toward automation in hospitals and clinical laboratories is another key driver of the global automatic coagulation system market. Hospitals and laboratories worldwide are adopting automation technologies to improve operational efficiency, reduce labor costs, and enhance diagnostic accuracy. Automated coagulation systems are part of this broader move toward digitalization, as they offer the ability to handle large volumes of samples efficiently while maintaining high levels of precision. The demand for high-throughput testing in hospitals, particularly in busy emergency departments and intensive care units, is driving the adoption of automated coagulation systems. These systems help speed up diagnostics, ensuring that healthcare providers receive accurate results within a short time frame, which is crucial for critical care patients. Automation helps reduce human error in testing procedures, improving the reliability of diagnostic results. As hospitals and laboratories increasingly focus on improving patient outcomes and operational efficiency, automated coagulation testing solutions will continue to play a key role in meeting these goals.
Rising Awareness About Blood Disorders and Coagulation Testing
There has been a significant rise in public and professional awareness regarding blood disorders and the importance of coagulation testing. Educational campaigns, greater access to information, and improved healthcare services have contributed to this heightened awareness. Patients are becoming more proactive in seeking medical attention for symptoms associated with blood clotting disorders, such as unusual bruising, swelling, or pain in the limbs. Healthcare providers are also more focused on preventive care and early diagnosis of conditions like hemophilia, DVT, and PE. This awareness is leading to an increased demand for more advanced coagulation testing methods, particularly those that provide quick, accurate, and cost-effective results. Automated coagulation systems cater to this growing demand by providing accurate and timely results, which are crucial for early diagnosis and treatment. As more people understand the risks of untreated coagulation disorders, the need for regular testing, especially in at-risk populations such as the elderly and those with chronic diseases, is increasing.
Technological Integration with Electronic Health Records (EHR) Systems
The integration of coagulation testing systems with electronic health records (EHR) is another significant driver of market growth. The growing trend of digitizing patient records and integrating clinical workflows is making it easier for healthcare providers to access test results, track patient progress, and make data-driven decisions. Automated coagulation systems that are compatible with EHR platforms allow for seamless transfer of test results, reducing the time between testing and treatment decisions. This integration also improves the overall quality of patient care by providing healthcare providers with a comprehensive view of a patient’s medical history, coagulation status, and treatment progress. The ability to track coagulation profiles over time, combined with the real-time data provided by automated systems, enables more personalized and efficient patient management. This integration further drives the adoption of automated coagulation systems, particularly in large hospitals and multi-facility healthcare networks.
Segmental Insights
Type Insights
Based on the Type, fully automatic coagulation systems are currently dominating the market. These systems are preferred by healthcare providers due to their ability to streamline the coagulation testing process, offering higher efficiency, accuracy, and reduced human intervention compared to semi-automatic systems. The increasing complexity of coagulation disorders and the growing demand for precision in patient monitoring are key factors driving the adoption of fully automated systems.
Fully automatic coagulation systems are designed to handle a wide range of coagulation tests with minimal manual input, reducing the possibility of human error and increasing the speed of diagnostics. These systems can automatically process large volumes of samples, making them highly suited for busy hospital laboratories, central testing laboratories, and clinical environments where rapid, high-throughput testing is critical. They are particularly advantageous in high-demand clinical settings such as emergency departments, intensive care units, and large medical centers, where the need for fast, accurate coagulation results is paramount to guide critical treatment decisions. Fully automated systems are equipped with integrated software that can store patient data, generate reports, and even integrate results with electronic health records (EHR), enhancing the overall efficiency of healthcare workflows.
In addition to speed and accuracy, fully automatic systems are known for their consistency in delivering high-quality results. With minimal human intervention, there is less risk of variation in testing procedures, which is particularly important when managing coagulation disorders like hemophilia, thrombophilia, or when monitoring patients on anticoagulation therapy. These patients require continuous and precise monitoring, which makes the automation of testing critical. Fully automatic systems often offer additional features, such as automatic reagent handling, quality control checks, and system calibration, ensuring that results are reliable and compliant with regulatory standards.
Application Insights
Based on the Application segment, hospitals are the dominant market players. This dominance can be attributed to several factors, including the high volume of coagulation tests performed in hospital settings, the critical nature of coagulation management in patient care, and the need for advanced and reliable diagnostic tools. Hospitals, especially large medical centers and teaching hospitals, often cater to a diverse patient base, including those with coagulation disorders such as hemophilia, deep vein thrombosis (DVT), pulmonary embolism, and those requiring anticoagulant therapy. This drives the demand for automated coagulation testing systems that provide quick, accurate, and high-throughput results essential for effective treatment decisions.
Hospitals have a significant advantage in utilizing fully automated coagulation systems, as these systems can efficiently handle high volumes of samples and provide real-time, precise test results with minimal human intervention. In a hospital environment, where the need for fast and accurate diagnostics is critical, automated coagulation systems ensure that patient outcomes are optimized by reducing turnaround times and minimizing the risk of human error in testing. These systems allow healthcare professionals to monitor patients on anticoagulant therapy, evaluate coagulation status pre- and post-surgery, and assist in the management of patients with clotting disorders, all of which are vital for managing complex and acute conditions. The integration of automated coagulation systems with hospital information systems (HIS) and laboratory information management systems (LIMS) enhances the overall efficiency of healthcare operations. Data from coagulation tests can be seamlessly shared across different departments, allowing healthcare providers to make more informed decisions in real-time. This level of integration is particularly important in hospital settings where interdisciplinary collaboration is often required, especially for critically ill patients who need continuous coagulation monitoring. As hospitals continue to adopt digitized solutions and move toward more integrated and patient-centered care, the adoption of advanced automatic coagulation systems becomes even more essential to meet the growing demand for precision medicine.
Regional Insights
North America was the dominant region. This dominance can be attributed to several factors, including the region's advanced healthcare infrastructure, high healthcare expenditure, and the increasing prevalence of coagulation disorders. The United States, in particular, stands out as the largest market in North America, driven by its state-of-the-art medical technology, widespread adoption of automated healthcare systems, and high demand for precision diagnostics in hospital settings.
North America's healthcare systems are among the most advanced globally, with hospitals and diagnostic laboratories extensively investing in cutting-edge technologies like automated coagulation systems. These systems are crucial in clinical environments where rapid, accurate testing is necessary for managing patients with coagulation disorders such as hemophilia, deep vein thrombosis (DVT), and other clotting-related conditions. As a result, healthcare providers in North America are increasingly relying on automatic coagulation testing systems to streamline testing, improve patient care, and reduce errors associated with manual testing.
The region’s dominance is also supported by the growing awareness of the importance of regular coagulation monitoring, especially among patients undergoing long-term anticoagulant therapy, such as those on warfarin. Hospitals in North America are particularly focused on enhancing the quality of care for these patients, and automated coagulation systems play a crucial role in ensuring accurate and timely results. The integration of automated coagulation systems with digital health solutions, such as electronic health records (EHR) and laboratory information management systems (LIMS), enhances overall healthcare efficiency, further boosting their adoption in North America.
Key Market Players
• Beijing Succeeder Technology, Inc.
• Cardinal Health, Inc.
• Dymind Biotechnology Co. Ltd.
• Erba Group
• HORIBA, Ltd.
• Labtron Equipment Ltd
• Linear Chemicals, S.L.U.
• Maccura Biotechnology Co., Ltd.
• Seleo S.R.L.
• Thermo Fisher Scientific, Inc.
Report Scope:
In this report, the Global Automatic Coagulation System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Automatic Coagulation System Market, By Type:
o Fully Automatic
o Semi-Automatic
• Automatic Coagulation System Market, By Application:
o Hospital
o Biotechnology Company
o Clinics
o Others
• Automatic Coagulation System Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Automatic Coagulation System Market.
Available Customizations:
Global Automatic Coagulation System market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Automatic Coagulation System Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Fully Automatic and Semi-Automatic)
5.2.2. By Application (Hospital, Biotechnology Company, Clinics, and Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Automatic Coagulation System Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Automatic Coagulation System Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Application
6.3.2. Canada Automatic Coagulation System Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Application
6.3.3. Mexico Automatic Coagulation System Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Application
7. Europe Automatic Coagulation System Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Automatic Coagulation System Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.2. United Kingdom Automatic Coagulation System Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.3. Italy Automatic Coagulation System Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.4. France Automatic Coagulation System Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.5. Spain Automatic Coagulation System Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
8. Asia-Pacific Automatic Coagulation System Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Automatic Coagulation System Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.2. India Automatic Coagulation System Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.3. Japan Automatic Coagulation System Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
8.3.4. South Korea Automatic Coagulation System Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Application
8.3.5. Australia Automatic Coagulation System Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Application
9. South America Automatic Coagulation System Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Automatic Coagulation System Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.2. Argentina Automatic Coagulation System Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.3. Colombia Automatic Coagulation System Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
10. Middle East and Africa Automatic Coagulation System Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Automatic Coagulation System Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.2. Saudi Arabia Automatic Coagulation System Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.3. UAE Automatic Coagulation System Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Beijing Succeeder Technology, Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Cardinal Health, Inc.
14.3. Dymind Biotechnology Co. Ltd.
14.4. Erba Group
14.5. HORIBA, Ltd.
14.6. Labtron Equipment Ltd
14.7. Linear Chemicals, S.L.U.
14.8. Maccura Biotechnology Co., Ltd.
14.9. Seleo S.R.L.
14.10. Thermo Fisher Scientific, Inc.
15. Strategic Recommendations
16. About Us & Disclaimer